Genentech, Inc.
NEWS
Genentech, a Roche company, presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer at the European Society for Medical Oncology Virtual Congress 2020 this weekend.
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
85% of participants in the trial of Actemra were from minority racial and ethnic groups, which are historically underrepresented in clinical studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
It was a busy week for clinical trial updates. Here’s a look.
Genetech provides new data on the recently approved drug Enspryng. Continue with the article to know more about the recent updates about this drug.
August has been a busy month for the U.S. Food and Drug Administration. The final two weeks are marked by a number of PDUFA dates, although a few of those drugs have already been approved.
The U.S. Food and Drug Administration approved Genentech’s Enspryng (satralizumab-mwge) as a subcutaneous treatment for adults with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder.
It was a very busy week for clinical trial updates. Here’s a look.
JOBS
IN THE PRESS